Furthermore, a recent clinical study of PF-04136309, a CCR2 inhibitor, in combination with nab-paclitaxel and gemcitabine has found severe adverse effects by this regimen including pulmonary toxicity in patients with pancreatic ductal adenocarcinoma [209]. The gene discussed is CCR2; the disease is pancreatic ductal adenocarcinoma.